---
title: Cell and Gene Therapy Catapult vs Omniabio
slug_a: ct
slug_b: omniabio
site: cdmo
review_signal_gate: closed
canonical_path: /compare/ct/omniabio
generated_by: BioBM Editorial AI
---

# Cell and Gene Therapy Catapult vs Omniabio

This comparison is auto-generated by BioBM Editorial AI and intended as an evidence-oriented side-by-side reference.

## Company A

Cell and Gene Therapy Catapult (ct) is listed for cdmo. UK-based innovation and manufacturing support organization for cell and gene therapies, offering infrastructure, expertise, and collaboration across the ATMP lifecycle.

Services: 13. Modalities: 3. Indications: 4. Locations: 5. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (13).

Review summary: Review summary withheld until site-level review gate opens.

## Company B

Omniabio (omniabio) is listed for cdmo. OmniaBio is a cell and gene therapy CDMO specializing in process development, analytical development, and GMP manufacturing for lentiviral vectors, iPSCs, and immune cell-based therapies. The company operates a 120,000 sq ft facility in Hamilton, Ontario, integrating AI, automation, and robotics to deliver scalable manufacturing from preclinical to commercial stages.

Services: 8. Modalities: 2. Indications: 0. Locations: 1. Certifications: 0. Directory-wide review aggregates for this site are withheld until the review signal gate opens. The strongest documented coverage currently appears in services (8).

Review summary: Review summary withheld until site-level review gate opens.